181 related articles for article (PubMed ID: 33895403)
1. Prolonged Lenalidomide Therapy Does Not Impact Autologous Peripheral Blood Stem Cell Mobilization and Collection in Multiple Myeloma Patients: A Single-Center Retrospective Analysis.
Cowan AJ; Stevenson PA; Green DJ; Tuazon S; Libby EN; Kwok M; Lee S; Coffey DG; Gopal AK; Holmberg LA
Transplant Cell Ther; 2021 Aug; 27(8):661.e1-661.e6. PubMed ID: 33895403
[TBL] [Abstract][Full Text] [Related]
2. Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials.
Kauer J; Freundt EP; Schmitt A; Weinhold N; Mai EK; Müller-Tidow C; Goldschmidt H; Raab MS; Kriegsmann K; Sauer S
BMC Cancer; 2023 Nov; 23(1):1132. PubMed ID: 37990162
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma.
Bhutani D; Zonder J; Valent J; Tageja N; Ayash L; Deol A; Al-Kadhimi Z; Abrams J; Lum L; Ratanatharathorn V; Uberti J; Abidi MH
Support Care Cancer; 2013 Sep; 21(9):2437-42. PubMed ID: 23591714
[TBL] [Abstract][Full Text] [Related]
4. Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor: A Report From The Covid Era.
Rybinski B; Rapoport AP; Badros AZ; Hardy N; Kocoglu M
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e716-e729. PubMed ID: 35504807
[TBL] [Abstract][Full Text] [Related]
5. Impact of Clinical Parameters and Induction Regimens on Peripheral Blood Stem-Cell Mobilization and Collection in Multiple Myeloma Patients.
Sauer S; Hieke L; Brandt J; Müller-Tidow C; Schmitt A; Kauer J; Kriegsmann K
Transfus Med Hemother; 2023 Oct; 50(5):382-395. PubMed ID: 37899996
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of six cycles of lenalidomide-based triplet induction before stem cell collection for newly diagnosed transplant-eligible multiple myeloma.
Yoshihara S; Yoshihara K; Shimizu Y; Imado T; Takatsuka H; Kawamoto H; Misawa M; Ifuku H; Ohe Y; Okada M; Fujimori Y
Hematology; 2021 Dec; 26(1):388-392. PubMed ID: 34000225
[TBL] [Abstract][Full Text] [Related]
7. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma.
Kumar S; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Gastineau DA; Litzow MR; Fonseca R; Roy V; Rajkumar SV; Gertz MA
Leukemia; 2007 Sep; 21(9):2035-42. PubMed ID: 17581613
[TBL] [Abstract][Full Text] [Related]
8. Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation.
Moreb JS; Byrne M; Shugarman I; Zou F; Xiong S; May WS; Norkin M; Hiemenz J; Brown R; Cogle C; Wingard JR; Hsu JW
J Clin Apher; 2018 Feb; 33(1):29-37. PubMed ID: 28556233
[TBL] [Abstract][Full Text] [Related]
9. Local Radiation Therapy Before and During Induction Delays Stem Cell Mobilization and Collection in Multiple Myeloma Patients.
Sauer S; Erdmann K; Jensen AD; Wennmann M; Pavel P; Jordan K; Schmitt A; Kriegsmann M; Wuchter P; Goldschmidt H; Müller-Tidow C; Kriegsmann K
Transplant Cell Ther; 2021 Oct; 27(10):876.e1-876.e11. PubMed ID: 34214737
[TBL] [Abstract][Full Text] [Related]
10. Impact of Plerixafor Use at Different Peripheral Blood CD34
Shah EE; Young RP; Wong SW; Damon LE; Wolf JL; Shah ND; Leavitt AD; Loeffler P; Martin TG
Biol Blood Marrow Transplant; 2020 May; 26(5):876-883. PubMed ID: 31785375
[TBL] [Abstract][Full Text] [Related]
11. Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen.
Nazha A; Cook R; Vogl DT; Mangan PA; Gardler M; Hummel K; Cunningham K; Luger SM; Porter DL; Schuster S; O'Doherty U; Siegel D; Stadtmauer EA
Bone Marrow Transplant; 2011 Jan; 46(1):59-63. PubMed ID: 20421869
[TBL] [Abstract][Full Text] [Related]
12. Impact of lenalidomide on collected hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affected.
Dosani T; Covut F; Pinto R; Kim BG; Ali N; Beck R; Maitta R; Downes K; Fox R; Reese J; de Lima M; Malek E
Leuk Lymphoma; 2019 Sep; 60(9):2199-2206. PubMed ID: 30845862
[TBL] [Abstract][Full Text] [Related]
13. Addition of bortezomib to high-dose cyclophosphamide therapy as a conditioning regimen for autologous peripheral blood stem cell harvest leads to an increased yield of hematopoietic stem cells.
Ohno S; Hayashi K; Shimizu R; Ishii A; Tanaka H
J Clin Exp Hematop; 2022 Sep; 62(3):147-153. PubMed ID: 35979578
[TBL] [Abstract][Full Text] [Related]
14. Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center.
Pozotrigo M; Adel N; Landau H; Lesokhin A; Lendvai N; Chung DJ; Chimento D; Riedel E; Chen X; Reich L; Comenzo R; Giralt S; Hassoun H
Bone Marrow Transplant; 2013 Aug; 48(8):1033-9. PubMed ID: 23334269
[TBL] [Abstract][Full Text] [Related]
15. Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma.
Sahin U; Demirer T
J Clin Apher; 2018 Jun; 33(3):357-370. PubMed ID: 28980709
[TBL] [Abstract][Full Text] [Related]
16. Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure.
Costa LJ; Abbas J; Hogan KR; Kramer C; McDonald K; Butcher CD; Littleton A; Shoptaw K; Kang Y; Stuart RK
Bone Marrow Transplant; 2012 Nov; 47(11):1403-8. PubMed ID: 22484324
[TBL] [Abstract][Full Text] [Related]
17. Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide.
Micallef IN; Ho AD; Klein LM; Marulkar S; Gandhi PJ; Calandra G; McSweeney PA
Bone Marrow Transplant; 2011 Mar; 46(3):350-5. PubMed ID: 20479709
[TBL] [Abstract][Full Text] [Related]
18. Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy.
Cavallo F; Bringhen S; Milone G; Ben-Yehuda D; Nagler A; Calabrese E; Cascavilla N; Montefusco V; Lupo B; Liberati AM; Crippa C; Rossini F; Passera R; Patriarca F; Cafro AM; Omedè P; Carella AM; Peccatori J; Catalano L; Caravita T; Musto P; Petrucci MT; Boccadoro M; Palumbo A
Leukemia; 2011 Oct; 25(10):1627-31. PubMed ID: 21637283
[TBL] [Abstract][Full Text] [Related]
19. Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients.
Skopec B; Skerget M; Zontar D; Zadnik V; Zver S
Wien Klin Wochenschr; 2017 Aug; 129(15-16):545-551. PubMed ID: 28439700
[TBL] [Abstract][Full Text] [Related]
20. Third time's a charm? Mobilization of autologous peripheral blood stem cells in patients with two previous failed mobilizations with plerixafor.
Zhuang L; Boriboonnangkul P; Wang S; Yuan S
Transfusion; 2020 Jun; 60(6):1253-1259. PubMed ID: 32483875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
